Related Experiment Video

Updated: Jun 9, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy

Oliver Drews1, Osamu Tsukamoto, David Liem

  • 1School of Medicine, University of California-Los Angeles, 675 Charles E Young Drive, Los Angeles, CA 90095-1760, USA.

Circulation Research
|September 4, 2010
PubMed

Insights

Cardiac hypertrophy alters proteasome function, showing divergent regulation of 26S and 20S proteasome activities. cAMP-dependent protein kinase (PKA) signaling impacts proteasome function, offering potential therapeutic targets for heart failure.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Proteasome Biology

Background:

  • Proteasomal degradation is dysregulated in cardiac hypertrophy, a precursor to heart failure.
  • Previous work identified diverse proteasome subpopulations in the heart, with complex regulatory mechanisms.

Purpose of the Study:

  • To elucidate the molecular mechanisms driving altered proteasome function in the hypertrophic heart.
  • To investigate the role of cAMP-dependent protein kinase (PKA) in regulating proteasome activity during cardiac hypertrophy.

Main Methods:

  • Analysis of proteasome function, expression, and assembly in a mouse model of cardiac hypertrophy induced by beta-adrenergic stimulation.
  • Measurement of distinct proteasome proteolytic activities (26S ATP-dependent, 20S ATP-independent).

Main Results:

  • Cardiac hypertrophy exhibits divergent regulation of proteasome activities: 26S proteasome activities are enhanced, while 20S proteasome caspase- and trypsin-like activities are decreased.
  • Increased expression and assembly of 19S subunits contribute to enhanced 26S proteasome activity.
  • Activation of cAMP-dependent protein kinase (PKA) restored depressed 20S proteasome functions, indicating PKA as a positive regulator.
  • Chymotrypsin-like 20S activity remained stable, suggesting a shift in proteasome subpopulations due to altered subunit expression.

Conclusions:

  • Novel regulatory mechanisms in cardiac hypertrophy include increased inducible subunit incorporation into 20S proteasomes, enhanced 20S sensitivity to PKA, and increased 26S assembly.
  • PKA modulation of proteasome complexes presents a potential therapeutic strategy for restoring cardiac function in diseased hearts.
Abstract

More Related Videos

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...